

1/32

| Clone | KD (pM) | kon(1/Ms) | kdis(1/s) |
|-------|---------|-----------|-----------|
| 3C3   | 10.7    | 8.13E+05  | 8.67E-06  |
| 3G5   | 3.3     | 9.05E+05  | 2.97E-06  |
| 1B4   | 10.5    | 8.32E+05  | 8.76E-06  |
| 3B6   | 7.9     | 7.82E+05  | 6.14E-06  |
| 6H6   | 2.8     | 9.05E+05  | 2.49E-06  |

FIG. 1




FIG. 2




FIG. 3





FIG. 4A

FIG. 4B

CD40L Blocking



6/32




FIG. 5




FIG. 6

7/32





FIG. 7A

FIG. 7B






FIG. 8A

9/32




FIG. 8B

10/32




FIG. 9A




FIG. 9B




FIG. 10A

12/32




FIG. 10B

13/32




FIG. 11A




FIG. 11B

FIG. 12





FIG. 13






FIG. 14A




FIG. 14B




FIG. 15

19/32




FIG. 16




FIG. 17

20/32




FIG. 18





FIG. 20



FIG. 21

Full length aa 1-173




aa 1-94 CRD 1 + 2

aa 36-130 CRD 2 + 3



aa 84-173 CRD 3 + 4

22/32



23/32

FIG. 22



24/32

FIG. 23A





FIG. 23B



25/32

FIG. 23C





FIG. 24



27/32

FIG. 25A





FIG. 25B



28/32

FIG. 25C







FIG. 26



29/32

FIG. 27



30/32




FIG. 28




FIG. 29

31/32




FIG. 30

32/32

## Cytokine response in whole blood assay

|                | IL-1 $\beta$ |         |         |         |         |
|----------------|--------------|---------|---------|---------|---------|
|                | Donor 1      | Donor 2 | Donor 3 | Donor 4 | Donor 5 |
| hulgG2 control | 0.2          | 1.4     | 1.6     | 13      | 4.5     |
| LPS            | 682          | 697     | 885     | 882     | 858     |
| 3C3            | 0.1          | 1.3     | 1       | 11.3    | 5.6     |
|                | IL-6         |         |         |         |         |
|                | Donor 1      | Donor 2 | Donor 3 | Donor 4 | Donor 5 |
| hulgG2 control | 2.1          | 1       | 12.3    | 1.3     | 2.9     |
| LPS            | 12.5         | 12.6    | 11.6    | 11.7    | 16      |
| 3C3            | 1.9          | 0.9     | 11      | 1.2     | 2.5     |
|                | TNF $\alpha$ |         |         |         |         |
|                | Donor 1      | Donor 2 | Donor 3 | Donor 4 | Donor 5 |
| hulgG2 control | 0.6          | 0.7     | 1.4     | 1       | 1.3     |
| LPS            | 45.2         | 43.9    | 48.7    | 45.6    | 27.5    |
| 3C3            | 0.7          | 1.2     | 1.5     | 1.1     | 1.6     |
|                | IFN $\gamma$ |         |         |         |         |
|                | Donor 1      | Donor 2 | Donor 3 | Donor 4 | Donor 5 |
| hulgG2 control | BD           | BD      | BD      | BD      | 0.5     |
| LPS            | BD           | BD      | BD      | 49.8    | BD      |
| 3C3            | BD           | BD      | BD      | BD      | 1.3     |

FIG. 31